Trinity College (Dublin)
Latest From Trinity College (Dublin)
Ensysce Biosciences Inc. is developing a nanoscaled delivery system that might work for many types of potential drugs but will first be applied to siRNAs, a class of drug candidates that inspired tremendous excitement a decade ago, but has since been abandoned by many of its former champions. The Houston, TX-based start-up believes it can harness single-walled carbon nanotubes to deliver siRNAs that will block or “silence” the genetic instructions encoded by messenger RNA, and thereby stop targeted genes from producing disease-related protein.
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
Irish biotech Opsona Therapeutics recently raised $43 million with the help of four corporate VCs, for use in developing its potential first-in-class product for preventing delayed graft function in high-risk renal transplant patients.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.